| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to a study on the use of psychedelic therapies in the |
|
|
treatment of certain conditions. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. (a) In this Act: |
|
|
(1) "Department" means the Department of State Health |
|
|
Services. |
|
|
(2) "Psychedelic therapies" means the use of |
|
|
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine |
|
|
to treat mental health or other medical conditions. |
|
|
(b) The department, in consultation with Baylor College of |
|
|
Medicine and the Center for Psychedelic Research and Therapy at |
|
|
Dell Medical School at The University of Texas at Austin, shall |
|
|
conduct a study on the use of psychedelic therapies for treatment of |
|
|
post-traumatic stress disorder, depression, and other co-occurring |
|
|
conditions. |
|
|
(c) In conducting the study, the department shall: |
|
|
(1) review clinical trials on the efficacy of using |
|
|
psychedelic therapies in the treatment of post-traumatic stress |
|
|
disorder, depression, and other co-occurring conditions; |
|
|
(2) review current literature regarding the use of |
|
|
psychedelic therapies in the treatment of post-traumatic stress |
|
|
disorder, depression, and other co-occurring conditions; |
|
|
(3) review actions of the United States Food and Drug |
|
|
Administration regarding psychedelic therapies for treatment of |
|
|
post-traumatic stress disorder, depression, and other co-occurring |
|
|
conditions; |
|
|
(4) evaluate treatment guidelines for use of |
|
|
psychedelic therapies to treat post-traumatic stress disorder, |
|
|
depression, and other co-occurring conditions and recommend |
|
|
guidelines and best practices for providers; and |
|
|
(5) evaluate patient access to current treatment for |
|
|
post-traumatic stress disorder, depression, and other co-occurring |
|
|
conditions and recommend legislative or other actions necessary to |
|
|
ensure patient access to psychedelic therapies following approval |
|
|
by the United States Food and Drug Administration, including |
|
|
considerations of provider availability, affordability, |
|
|
accessibility, training and licensure, and other regulatory |
|
|
requirements. |
|
|
(d) Not later than December 1, 2026, the department shall |
|
|
submit to the governor, the lieutenant governor, the speaker of the |
|
|
house of representatives, and the chair of the standing committee |
|
|
of each house of the legislature with primary jurisdiction over the |
|
|
department a written report that includes: |
|
|
(1) the results of the study conducted under this |
|
|
section; and |
|
|
(2) any recommendations for legislative or other |
|
|
action necessary to ensure patient access to psychedelic therapies |
|
|
for treatment of post-traumatic stress disorder, depression, and |
|
|
other co-occurring conditions after those therapies are approved by |
|
|
the United States Food and Drug Administration. |
|
|
(e) This Act expires September 1, 2027. |
|
|
SECTION 2. This Act takes effect September 1, 2025. |